Elevation of intracranial soluble amyloid-b (Ab) levels has been implicated in the pathogenesis of Alzheimer's disease (AD). Intracellular events in neurons, which lead to memory loss in AD, however, remain elusive. Humanin (HN) is a short neuroprotective peptide abolishing Ab neurotoxicity. Recently, we found that HN derivatives activate the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling axis. We here report that an HN derivative named colivelin completely restored cognitive function in an AD model (Tg2576) by activating the JAK2/STAT3 axis. In accordance, immunofluorescence staining using a specific antibody against phospho-(p-) STAT3 revealed that p-STAT3 levels in hippocampal neurons age-dependently decreased in both AD model mice and AD patients. Intracerebroventricular administration of Ab1-42 downregulated p-STAT3 whereas passive immunization with anti-Ab antibody conversely restored hippocampal p-STAT3 levels in Tg2576 mice, paralleling the decrease in the brain Ab burden. Ab1-42 consistently modulated p-STAT3 levels in primary neurons. Pharmacological inhibition of the JAK2/STAT3 axis not only induced significant loss of spatial working memory by downregulating an acetylcholine-producing enzyme choline acetyltransferase but also desensitized the M 1 -type muscarinic acetylcholine receptor. Thus, we propose a novel theory accounting for memory impairment related to AD: Ab-dependent inactivation of the JAK2/STAT3 axis causes memory loss through cholinergic dysfunction. Our findings provide not only a novel pathological hallmark in AD but also a novel target in AD therapy.
Introduction
Amyloid-b (Ab), the main component of senile plaques, has long been implicated in the pathogenesis of Alzheimer's disease (AD). 1, 2 A variety of studies have indicated that elevation of Ab levels has been invariably found in a number of AD models in vitro and in vivo and also that enforced elevation of Ab causes cognitive dysfunction. 3 However, intracellular events in neurons under such high soluble Ab concentrations, which cause cognitive deficit, remain elusive. In addition, a recent prospective study analyzing brain pathology has revealed that about one third of the cases of a cognitively normal elderly population also showed AD-like brain pathology, such as senile plaques, 4 suggesting that there might be certain regulatory factors besides elevated Ab burden that determine cognitive function in AD patients; that is, some intraneuronal factors may regulate the vulnerability of neurons to AD-relevant neurotoxicity such as soluble Ab. It is, therefore, essential to elucidate neuronal intracellular events related to AD pathogenesis.
Humanin (HN) is a short neuroprotective peptide isolated from an occipital lobe of an AD patient where loss of neurons is mild as compared with those in other cerebral regions. 5, 6 HN abolishes neuronal death in vitro caused by various types of AD-related toxicities such as overload of toxic Ab peptides and overexpression of mutant familial AD (FAD) genes. 5, 7 In our previous studies, we found that HN derivatives including S14G-HN and colivelin (CLN) activate signal transducer and activator of transcription 3 (STAT3) and its regulator kinase Janus kinase 2 (JAK2) in vitro 8 and in vivo, 9,10 which may explain the pharmacological effect of HN and its derivatives. Given that the activation of the JAK2/STAT3 axis is directly involved in HN-mediated improvement of memory, the JAK2/STAT3 signaling axis may have a physiological role in cognitive function and may have possible implications in the AD-relevant memory impairment.
STATs have been reported to have a variety of roles in cellular function such as cell proliferation, differentiation and death. 11 Seven STAT family members have so far been identified: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. These factors are known to be important cellular mediators of cytokine receptor signaling. Upon Tyr phosphorylation by JAKs, STATs are transferred to the nucleus and transcriptionally regulate the expression of target genes. Among the STATs, STAT3 seems to be essential for embryonic development because STAT3-null mice die in the early embryonic stage. 12 However, the physiological roles of STAT3 in postmitotic neurons are not well understood except that it is involved in leptin-mediated control of food intake. 13 In the present study, we delineate the role of the JAK2/STAT3 signaling axis in AD-related memory loss, especially focusing on the effect of Ab on the activity of the JAK2/STAT3 axis. We also address the relevance of the JAK2/STAT3 axis to the cholinergic neurotransmission.
Materials and methods
Peptides, antibodies and materials CLN (SALLRSIPAPAGASRLLLLTGEIDLP) and activity-dependent neurotrophic factor 9 (ADNF9) (SAL-LRSIPA) were synthesized as described. 9 Rabbit antibodies against phospho-JAK2 (Tyr 1007/1008 ), phospho-STAT3 (Tyr   705   ) , phospho-extracellular signalregulated kinase 1/2 (ERK1/2) (Thr 202 /Tyr 204 ), total JAK2 (24B11) and total STAT3 (79D7) were from Cell Signaling Technology (Beverly, MA, USA). Affinitypurified goat polyclonal antibody against choline acetyltransferase (ChAT) was from Chemicon (Temecula, CA, USA). Mouse monoclonal antibody against Ab1-16 (6E10) was from Biosource (Camarillo, CA, USA). Mouse normal immunoglobulin G1 (IgG1) was from R&D Systems (Minneapolis, MN, USA). Rabbit polyclonal antibodies against total-ERK1 and M 1 muscarinic acetylcholine receptor (mAChR) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A rabbit polyclonal antibody against suppressor of cytokine signaling 3 (SOCS3) was from IBL (Gunma, Japan). A rabbit polyclonal antibody against Src homology-containing tyrosine phosphatase 2 (SHP2) was from Abcam (Cambridge, UK). AG490, AG43, JAK2 inhibitor II, a cell-permeable STAT3 inhibitor and a rabbit polyclonal antibody against protein inhibitor of activated STAT3 (PIAS3) were from Calbiochem (San Diego, CA, USA). Carbamylcholine chloride (carbachol, CCh), tacrine, and rabbit polyclonal antibodies against actin and MAP2 were from Sigma-Aldrich (St. Louis, MO, USA). Ab1-42 was from Peptide Institute (Osaka, Japan). Interleukin-6 (IL-6) was from Peprotech Inc. (Rocky Hill, NJ, USA). The enzyme-linked immunosorbent assay (ELISA) kit for p-STAT3 (Tyr 705 ) (Pathscan, no. 7300) was from Cell Signaling Technology. ELISA kits for human Ab1-40 (no. 298-64601) and Ab1-42 (HighSensitive, no. 296-64401) were from Wako (Tokyo, Japan). Other reagents described here are commercially available.
Animals and treatments
This study was conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals of KEIO University School of Medicine. All experimental procedures were approved by the Institutional Animal Experiment Committee at KEIO University. V642I-KIs were described.
14 Tg2576 mice (Tg2576s) 15 were purchased from Taconic (Germantown, NY, USA). L286V-PS1 transgenic mice (L286V-PS1 Tgs) 16 were kindly provided by Dr T Tabira (National Center for Geriatrics and Gerontology, Japan). ICR mice (CD-1) were from Charles River Japan Inc. (Kanagawa, Japan).
Intranasal (i.n.) administration of CLN was performed as described previously. 10 Briefly, mice were i.n. given 10 ml vehicle (sterile deionized distilled water (ddw) containing 5% sefsol and 20% isopropanol), with or without the indicated amounts of synthetic CLN peptides, under anesthesia with diethyl ether. Intracerebroventricular (i.c.v.) injection of Ab1-42 (300 pmol in 3 ml sterile ddw containing 10% dimethyl sulfoxide (DMSO)) was stereotaxically performed in the left lateral ventricles of 8-week-old male ICR mice (anterior-posterior, þ 0.3 mm; lateral, 1.0 mm; horizontal, 3.0 mm from the bregma). 17 At 7 days after the injection, mice were tested in Y mazes (YMs). Injection of vehicle (i.c.v., DMSO:saline = 1:1), AG490 (50 nmol in 5 ml vehicle), or AG43 (50 nmol in 5 ml vehicle) was similarly performed three times at 48-h intervals. At 24 h after the last i.c.v. injection, mice were tested in YM. Passive immunization of Tg2576s was similarly performed with i.c.v. injection of normal mouse IgG1 or mouse monoclonal anti-Ab antibody 6E10 (5 mg per injection) three times at 7-day intervals. Intrahippocampal injection of LacZ-or dominant negative-(DN-)STAT3-encoding adenoviruses was also stereotaxically performed in both sides of the hippocampal CA1 regions (anteriorposterior, þ 1.8 mm; lateral, 1.0 mm; horizontal, 1.3 mm from the bregma, 1 Â 10 7 viruses per injection, in 2 ml phosphate-buffered saline, PBS). At 5 days after the viral infection, CCh (in saline) was i.p. administered to the mice.
Behavioral tests
Open-field tests (OF) were performed as described. 14 Briefly, mice were individually placed at the center of a 100-cm 2 gray plastic field (with 20-cm interval black grids) surrounded by a 20-cm wall, and allowed to move freely for 3 min. Ambulation was measured, defined as the total grid line crossing. YM was performed as described. 14, 17 The apparatus for YM was made of gray plastic, with each arm 40 cm long, 12 cm high, 3 cm wide at the bottom and 10 cm wide at the top. The three arms were connected at an angle of 1201. Mice were individually placed at the end of an arm and allowed to explore the maze freely for 8 min. Total arm entries and spontaneous alternation percentage (SA%) were measured. SA% was defined as a ratio of the arm choices that differed from the previous two choices ('successful choices') to total choices during the run ('total entry minus two' because the first two entries could not be evaluated). For example, if a mouse made 10 entries, such as 1-2-3-2-3-1-2-3-2-1, there are 5 successful choices in 8 total choices (10 entries minus 2). Therefore, SA% in this case is 62.5%.
The elevated-plus maze (EPM) apparatus was made of four crossed arms. 14, 18 Two arms were open (50 Â 10 cm grey plastic floor plate without wall), whereas the other two were closed (same floor plates with 20-cm-high transparent acrylic wall). The maze was set at 100 cm above the floor. Mice were allowed to explore the maze freely for 90 s. Examined parameters were: (1) transfer latency (the time elapsed until the first entry to a closed arm); (2) duration of the first stay in a closed arm (the time from the first entry to a closed arm to the first escape from the arm); (3) cumulative time spent in the open/closed arms.
Water-finding task (WFT) was performed to analyze latent learning or retention of spatial attention of the mice. 14, 19, 20 The testing apparatus consisted of a grey plastic rectangular open field (50 Â 30 cm, with a black 10-cm 2 grid) with a 15-cm wall, and a cubic alcove (10 Â 10 Â 10 cm) was attached to the center of one longer wall. A drinking tube was inserted through a hole at the center of the alcove ceiling, with the tip of the tube placed at 5 cm for training or at 7 cm for the trial from the floor. A mouse was first placed at the near-right corner of the apparatus and allowed to explore it freely for 3 min. Mice were omitted from the analysis when they could not find the tube within the 3-min exploration. After the training session, mice were deprived of water for 24 h. In the trial session, mice were again individually placed at the same corner of the apparatus and allowed to find and drink the water in the alcove. The elapsed times until the first entry into the alcove (entry latency, EL), until the first touching/sniffing/licking of the water tube (contacting latency, CL) and until the initiation of drinking from the water tube (drinking latency, DL) were measured.
Immunofluorescence staining, immunohistochemistry and cytochemistry Histological analysis was performed as described. 17, 21 Frozen brain sections at 10 mm prefixed by 4% paraformaldehyde (PFA), or 4% PFA-fixed primary hippocampal neurons (PHNs) were soaked with appropriate primary antibodies (p-STAT3, 1:100; ChAT, 1:50; M 1 (Santa Cruz Biotechnology), 1:50; M 1 (Abcam), 1:100; MAP2, 1:100) at 4 1C for more than 72 h and then with appropriate biotinylated secondary antibodies. They were further soaked with horseradish peroxidase (HRP)-labeled streptoavidin-biotin complex (Vectastain Elite ABC Kit; Vector, Burlingame, CA, USA) and were visualized by diaminobenzidine (DAB) or Tyramide-FITC (TSA kit; NEN; PerkinElmer, Boston, MA, USA). Stained sections were observed with a light microscope or a confocal laser microscope (Digital Eclipse C1; Nikon, Tokyo, Japan).
Fluorescence images were analyzed by Image J 1.37v. An average fluorescence intensity of the brain regions (nuclei of pyramidal neurons in dentate gyri (DG) and CA1 regions) was measured for each brain section and the measured values were averaged for each group to be compared. We compared the fluorescence image analysis with immunoblot (IB) analysis or ELISA-mediated p-STAT3 quantification and confirmed that it can be used for semi-quantification of p-STAT3 (Supplementary Figure 1) .
ChAT-immunoreactive neurons in the medial septa of five coronal sections (at 50 mm-interval) at around þ 0.8-0.6 mm anterior from the bregma (total 4 mm 2 ) were counted for each mouse and were averaged for each group to be compared.
Cell culture and phosphorylation assays F11 cells were grown in Ham's F12 medium containing 18% fetal bovine serum. Primary cortical neurons (PCNs) (2.5 Â 10 6 cells per well in poly-L-lysine-coated six-well plates) and PHNs (1.5 Â 10 6 cells per well) were prepared from E14 mouse embryos as described. 9 For ERK phosphorylation assays, 22 
Magnetic cell sorting
Magnetic cell sorting (MACS) was performed as described previously. 23 Mice were transcardially perfused with ice-cold PBS and the hippocampi were dissected as soon as possible. Dissected hippocampi were minced in ice-cold Hank's balanced salt solution, and then they were put into trypsin-EDTA (0.05%) containing phosphatase inhibitor cocktails 1 and 2 at 37 1C for 45 min to dissociate. After centrifugation at 1500 r.p.m. for 8 min, the pellets were completely suspended in IMag buffer (BD Biosciences, San Jose, CA, USA) by rigorous pipetting. Suspended cells were washed three times with IMag buffer. Then, the cells were coated with rabbit polyclonal anti-p75 NTR antibody (1:10; Santa Cruz Biotechnology), biotinylated anti-rabbit IgG (1:10; Vector), and streptavidin-conjugated magnetic beads (1:10; BD Biosciences) in 1 ml IMag buffer containing phosphatase inhibitor cocktails 1 and 2 at 4 1C for 45 min. Cells were magnetically sorted with BD IMag Separation Magnet (BD Biosciences) twice for 8 min to obtain p75 NTR-positive and negative cellular fraction.
Analysis of Ab40 and Ab42 in mouse brain
Mouse brain samples (cerebral cortices and hippocampi) were first homogenized in Tris-buffered saline (TBS, pH 7.6) and ultracentrifuged (500 000 g, 4 1C, 20 min). 24 Insoluble pellets were lysed in TBS containing 1 M sucrose and ultracentrifuged (500 000 g, 41C, 20 min). Insoluble pellets were further lysed in TBS containing 1% Triton-X 100 at 37 1C for 15 min and ultracentrifuged (500 000 g, 4 1C, 20 min). Insoluble pellets were then lysed in TBS containing 2% SDS at 37 1C for 15 min and ultracentrifuged (500 000 g, 25 1C, 20 min). Insoluble pellets were sonicated in 70% formic acid and ultracentrifuged (500 000 g, 41C, 20 min). Supernatants were diluted in DMSO and subjected to two-site ELISAs for human Ab. ELISAs for human Ab40 (BAN50/BA27 monoclonal antibody) and Ab42 (BAN50/BC05 monoclonal antibody) were performed according to the manufacturer's instructions. Absorbance at 450 nm was measured with a microplate reader (BioRad Model 550).
Semiquantitative RT-PCR Total RNA was extracted from PC12 cells that had been treated with or without CLN (100 pM), ADNF9 (100 pM) or IL-6 (50 ng ml À1 ) together with or without the STAT3 inhibitor peptide (250 nM), using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). First-strand cDNAs were synthesized from 1-mg total RNA using Omniscript reverse transcriptase 
Statistics
All values in the figures are shown as means±s.e.m. Statistical analysis was performed with one-way analysis of variance in which the a-value was set at 0.05 and was assessed, followed by Fischer's post hoc multiple comparison. All data were analyzed using StatView (ver.5.0.1) software.
Results

Intranasal colivelin treatment recovers memory in
Tg2576 by increasing p-STAT3 levels Very recently, we found that i.n. administered CLN attenuates memory impairment caused by scopolamine or i.c.v. injection of Ab, which was in parallel with STAT3 phosphorylation in whole hippocampal lysates. 10 To examine whether CLN activates STAT3 in hippocampal neurons directly, we first observed the central nervous system (CNS) delivery of Alexa680-labelled CLN (Alex-CLN) by a real-time in vivo fluorescence imager (eXplore Optix; GE Healthcare, Princeton, NJ, USA). We found that fluorescence intensity was significantly elevated in the whole cerebral region of an Alex-CLN-administered mouse within 30 min, whereas there was no change in that of vehicle-administered mouse ( Figure 1a ). We also histologically confirmed the CNS delivery of biotinylated-CLN by i.n. administration (Supplementary Figure 2a) . We then asked whether STAT3 in the hippocampal neurons was activated by i.n. CLN treatment. Performing immunofluorescence (IF) staining and IB analysis using an antibody specifically recognizing phosphorylated (p-) STAT3 (Tyr   705   ) , which is an active form of STAT3, we confirmed a significant elevation of p-STAT3 levels in the nuclei of neurons in the DG and CA1 region (CA1) of the hippocampi ( Supplementary Figures 2b-d) . Immunoreactivity to the anti-p-STAT3 antibody was completely inhibited by preabsorption with the p-STAT3 antigen (Supplementary Figure 3) , suggesting that immunoreactivity was highly specific to the p-STAT3 (Tyr   705   ) antigen. To test whether CLN-mediated attenuation of memory impairment was dependent on JAK2/STAT3 activity, we further examined the effect of a JAK2 inhibitor AG490 or its negative control compound AG43 on CLN-mediated suppression of scopolamineinduced memory impairment. We found that AG490, but not AG43, inhibited the effect of CLN on scopolamine ( Supplementary Figures 2e and f) . In this case, the p-STAT3 levels were consistently reduced by AG490, but not by DMSO or AG43 (Supplementary Figure 2g) . We also examined the effect of AG490 on CLN-mediated suppression of Abinduced memory impairment, finding that AG490 again inhibited the effect of CLN on Ab toxicity in vivo (Supplementary Figure 2h) . Collectively, it is suggested that the activation of the JAK2/STAT3 axis is required for CLN-mediated suppression of memory impairment caused by scopolamine or i.c.v. injection of Ab.
We next examined the effect of CLN on Tg2576 mice (Tg2576s) overexpressing the Swedish-type mutant of amyloid precursor protein (APP) transgene 15 at 14 months; these mice had already suffered memory impairment in a YM test (Figure 1c) . After i.n. administration of vehicle or CLN for 3 weeks, mice were again subjected to a series of behavioral tests: an OF test, a YM, an EPM test and a WFT. Voluntary activities in OF were not significantly different among the groups both before and after treatments (Figure 1b) . SA% (an index of spatial working memory) of Tg2576s, which was lower than that of WT littermates before treatments, recovered to the normal levels by CLN, but not by vehicle treatment (Figure 1c ). In EPM, Tg2576s with vehicle treatment exhibited loss of anxiety-they stayed significantly longer in the open arms and shorter in the closed arms as compared with WTs-which was reversed by CLN treatment (Figure 1d ). In WFT, CLN treatment also ameliorated latent memory deficits in Tg2576s: significant delay in EL, CL and DL were reversed to the normal levels detected in WTs with vehicle or CLN treatment (Figure 1e ). IF staining of the brain sections from the mice that underwent the behavioral tests, using the anti-p-STAT3 antibody, surprisingly revealed that p-STAT3 levels were reduced in DG and CA1 of Tg2576s with vehicle treatment and that CLN treatment brought the p-STAT3 levels completely up to the normal levels observed in WTs (Figures 1f and g ). Both Thioflavin T (TfT) staining and Ab ELISA assays showed no changes in Ab levels of these mice, suggesting that CLN recovered p-STAT3 levels to the normal levels without lowering the Ab burden (Figures 1h-l) . To confirm that the effect of CLN on Tg2576s was also dependent on the JAK2/STAT3 axis, we further examined the effect of AG490 on CLN-mediated attenuation of memory impairment in Tg2576s. Finally, we found that the effect of CLN on Tg2576s was completely suppressed by JAK2 inhibition, as it was on scopolamine-or Ab-induced memory impairment (Figure 1m ).
Age-dependent STAT3 inactivation in murine models of Alzheimer's disease Substitution of Ile for Val at residue 642 in an isoform of APP with 695 amino acids was identified as the first genetic mutation in FAD. 25 We previously generated a mouse line harboring the V642I mutation in the endogenous APP gene using the 'knock-in (KI)' technique, which resulted in increased Ab1-42 production and mild memory impairment at the age of 27 months.
14 To delineate the roles of STAT3 in the pathogenesis of AD, we examined the levels of p-STAT3 by IF staining of the brain sections from V642I-APP KI mice (V642I-KIs) at 6, 12, 20 and 28 months using the anti-p-STAT3 antibody. IF intensities in DG and CA1 of the hippocampi showed a slight tendency toward deterioration between 12 and 28 months in WTs (Figures 2a and b ; also see Supplementary Figure 4) . IF intensities in DG and CA1 were substantially decreased as aging in V642I-APPs (Figure 2a ). There was a statistically significant difference in the IF intensity between WTs and V642I-KIs at 28 months in Figure 5 ). We confirmed the age-and FAD gene-dependent p-STAT3 deterioration in the nuclei of hippocampal neurons in two distinct AD models:
Tg2576s and another Tg mouse line overexpressing an L286V mutant of presenilin 1 (PS1) (L286V-PS1 Tgs) 16 (Supplementary Figure 6) . To measure the p-STAT3 levels in hippocampal neurons biochemically, we collected p75 neurotrophin receptor (p75 NTR)-positive (p75 þ ) neurons in the hippocampi 26 by MACS and performed specific two-site sandwich ELISA for p-STAT3 of the lysates from p75 þ and p75 À cells (mainly consisting of glial cells). We found that p-STAT3 levels were significantly reduced in p75 þ cells from V642I-KIs at 30 months as compared with those from WTs at 30 months, whereas p-STAT3 levels were moderately increased in p75
À cells from V642I-KIs (Figure 2c ).
STAT3 inactivation in Alzheimer's disease patients
To examine the pathological relevance of the hippocampal neuronal downregulation of the p-STAT3 levels, we further performed IF staining in autopsied brain sections from clinically and pathologically diagnosed sporadic AD patients, comparing with young and age-matched cognitively normal controls. We used the anti-p-STAT3 antibody, which also recognizes human p-STAT3 (Tyr 705 ) (Figure 2d ). 
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Consistent with the findings in the AD models shown above, we found that IF intensity was significantly reduced in neurons of DG in AD patients as compared with those of the age-matched controls (Figures 2e  and f) . In addition, we also observed high p-STAT3 levels in DG and CA1 of the young controls that were assumed to have cognitive function superior to that of the control elders, suggesting that p-STAT3 levels are likely to decrease as humans age. Deterioration of p-STAT3 may occur earlier in CA1 regions than in DG: there was no statistically significant difference in the p-STAT3 levels between AD patients and agematched controls in CA1 whereas p-STAT3 levels in young controls were significantly higher than those of AD patients or age-matched controls (Figures 2e and f) . Thus, reduction of p-STAT3 levels in the hippocampal neurons is closely linked to the pathogenesis of AD.
Reciprocal correlation between Ab burden and p-STAT3 levels Elevation of soluble toxic Ab levels is a common feature shared by neuronal cells expressing mutants of the three known FAD genes. [27] [28] [29] To delineate the effect of Ab peptides on STAT3 phosphorylation, we performed i.c.v. injection of Ab1-42 into ICR mice. At 24 h or a week after the injection, mice were tested in YM. Injection of Ab1-42 (i.c.v.) significantly reduced SA% at a week after the injection (Figure 3a) , indicating that Ab1-42 induced memory impairment. In parallel, IF staining revealed that the p-STAT3 levels were significantly reduced by Ab1-42 at a week after the injection, especially in DG and CA1, but not in CA3 (Figure 3b ). In contrast, Ab1-42 treatment for 24 h did not induce memory impairment and resulted in a slight increase in p-STAT3 levels in the hippocampi (Supplementary Figure 7) .
Passive immunization with anti-Ab antibody has repeatedly been reported to attenuate not only the Ab pathology but also the memory impairment of AD-model mice. 30, 31 To examine whether the cerebral Ab overload causes STAT3 inactivation in AD, Tg2576s at 14 months were passively immunized with mouse monoclonal anti-Ab antibody (6E10) by i.c.v. injection. IF staining revealed that passive immunization with 6E10, but not with control mouse IgG1, significantly recovered p-STAT3 levels in the hippocampal neurons of Tg2576s (Figures 3d-f) , suggesting that the reduction of the p-STAT3 levels detected in Tg2576s at 14 months can be reversed by immunological depletion of Ab. We observed that fluorescence intensity and numbers of TfT-positive amyloid plaques in Tg2576s were reduced by treatment with 6E10, but not by that with control IgG1 (Figure 3g ). Using quantitative two-site sandwich ELISA for human Ab, we confirmed the significant reduction in brain Ab1-42 levels by 6E10 as compared with those by control IgG1 (Figures 3h and i) . Thus, p-STAT3 levels in the nuclei of hippocampal neurons were reciprocally correlated with the brain Ab burden.
Ab modulates p-STAT3 levels in primary neurons
We further examined the effect of toxic soluble Ab on STAT3 phosphorylation in primary cultured neurons in vitro. Treatment with 10 mM Ab1-42 for 24 h increased the p-STAT3 levels in PHNs. Upregulation of p-STAT3 at 24 h was induced only by 10 mM Ab1-42 treatment, but not by DMSO, Ab1-40 (1-10 mM), or low-dose Ab1-42 (1 mM), suggesting that p-STAT3 was specifically induced by toxic Ab1-42 at high concentrations (Figure 4a) . To delineate the mechanisms of p-STAT3 regulation, we also performed IB analysis using antibodies against ERK and well-known STAT3 suppressors such as suppressor of cytokine signaling 3 (SOCS3), 32 PIAS3, 33 and SHP2. 34 We found that p-STAT3 upregulation was in parallel with downregulation of SOCS3, PIAS3 and SHP2, suggesting that elevation of p-STAT3 levels was likely due to reduction of STAT3 suppressors (Figure 4a ). In this case, p-ERK levels were also upregulated by 10 mM Ab1-42. PCNs' response to 10 mM Ab1-42 was similar to that of PHNs, except that Ab did not induce downregulation of protein inhibitor of activated STAT3 (PIAS3) and Src homology-containing tyrosine phosphatase 2 (SHP2) or ERK phosphorylation in PCNs (Figure 4b ). To examine if longer Ab treatment downregulates p-STAT3, we treated PHNs with 10 mM Ab1-42 for 72 h. We found that Ab1-42 treatment substantially downregulated p-STAT3 levels at 72 h (Figure 4c ). Unexpectedly, we found that STAT3 suppressors such as SOCS3, PIAS3 and SHP2 were kept downregulated during the Ab treatment whereas p-ERK levels were kept high. Considering that prolonged ERK activation sometimes results in inhibition of STAT3 phosphorylation, 35 continuous high p-ERK levels caused by chronic Ab treatment are likely to induce p-STAT3 downregulation. We further characterized the lysates from PCNs and PHNs. Baseline p-STAT3 levels in PCNs were much higher than those in PHNs (Figure 4d ). Levels of t-STAT3, SOCS3, PIAS3 and SHP2 in PCNs were also higher than those in PHNs. In clear contrast, p-ERK levels in PCNs were much lower than those in PHNs. These data suggest that p-STAT3 levels in PHNs are more easily reduced than in PCNs, presumably caused by high p-ERK levels in PHNs.
To examine the relevance of FAD genes in primary neurons, we next prepared PCNs and PHNs from WT and Tg2576 embryos. Basal p-STAT3 levels were higher in PCNs derived from Tg2576s (WT vs Tg2576 = 1.00 vs 1.73 at 24 h), which overproduce Ab1-42, than in those from WTs, until 120 h after the preparation (Figure 4e, left panels) . On the other hand, p-STAT3 levels at 24 h were equal between PHNs from WTs and those from Tg2576s and then were gradually downregulated in PHNs from Tg2576s as compared with those from WTs (WT vs Tg2576 = 0.59 vs 0.35 at 120 h; Figure 4e , right panels), suggesting that an FAD mutant of APP induced p-STAT3 inactivation in PHNs. In addition, chronically coincubated (more than 72 h) Ab1-42 downregulated p-STAT3 levels predominantly in (Figure 4g ). Taken together, hippocampal neurons seem to be more sensitive to Ab-mediated inactivation of p-STAT3, which might explain the hippocampus-dominant p-STAT3 reduction in AD.
We further examined the effect of 6E10 on Ab-induced acute STAT3 phosphorylation. We found that 6E10, but (Figure 5a ). AG490 significantly impaired cognitive function in Tg2576s, whereas it did not significantly impaired cognitive function in WTs, suggesting that the downregulation of JAK2 causes memory impairment preferentially in Tg2576s. To examine the effect of AG490 on WT animals, we also performed i.c.v. injection of AG490 to ICR mice (50 nmol
(about 15 mg) per injection). AG490, but not vehicle or AG43, induced a significant decrease in SA% in YM, suggesting that inhibition of JAK2 resulted in memory impairment even in WT animals ( Figure 5b ). By IF and IB analysis, we confirmed that AG490 inactivated the JAK2/STAT3 axis in hippocampal neurons (Figures 5c  and d) . We also confirmed that another JAK2 inhibitor (JAK2 inhibitor II) induced memory impairment in WT animals in a dose-dependent fashion (Figure 5f ). Next, we examined the effect of AG490 on neurons expressing an acetylcholine-(ACh-)producing enzyme, ChAT, in the medial septa because the number of ChAT-positive neurons, which is diminished by AD-relevant insults such as i.c.v. injection of Ab, positively correlates with spatial working memory. 17 Immunohistochemical (IHC) staining revealed that the numbers of ChAT-positive neurons in the medial septa of AG490-injected mice were significantly fewer than those of vehicle-or AG43-injected mice, suggesting that the expression of ChAT in the medial septa is, at least, partially dependent on the activity of the JAK2/STAT3 axis (Figures 5c and e) .
We further examined the in vitro effect of STAT3 activation on gene expression by semiquantitative RT-PCR using mRNA derived from PC12 cells. CLN and interleukin-6 (IL-6), a general STAT3 activator, upregulated ChAT mRNA expression, whereas a nineamino-acid component of CLN named ADNF9 did not do so as reported 10 ( Figure 5g ). CLN upregulated VAChT and ChAT as well as an antiapoptotic molecule Bcl-2, which was completely inhibited by a cell-permeable STAT3 inhibitor (Figure 5h ), suggesting that STAT3 transcriptionally upregulates ChAT and VAChT and supports the basal forebrain cholinergic system. Inhibition of the JAK2/STAT3 axis desensitizes the M 1 muscarinic acetylcholine receptor Considering that HN derivatives such as CLN attenuate scopolamine-induced memory impairment within 30 min, 9,36 the JAK2/STAT3 axis may regulate function of mAChRs, independently of transcriptional regulation of a set of its target genes such as ChAT and VAChT (Figure 5h ). We therefore examined the effect of CLN on ERK phosphorylation induced by a muscarinic agonist, CCh, via the M 1 -type mAChR 22, 37 ( Supplementary Figures 8a and b) . Pretreatment for 30 min with CLN, but not with bovine serum albumin (BSA), augmented the ERK phosphorylation induced by CCh in F11 neurohybrid cells (Figure 6a) . Pretreatment with tacrine, a cholinesterase inhibitor, modestly increased CCh-induced p-ERK, presumably because of the inhibition of endogenous ACh degradation. The JAK2 inhibitor AG490, but not DMSO or AG43, suppressed CLN-mediated augmentation of CCh-induced p-ERK (Figure 6b ). In this case, AG490 without CLN pretreatment rather increased CCh-evoked p-ERK levels, presumably because of the toxicity of AG490 as reported. 38 We confirmed the data in another cell line, PC12 ( Supplementary  Figures 8c and d) . We also found that IL-6, a general STAT3 activator, increased CCh-induced p-ERK, which was inhibited by AG490 ( Supplementary  Figure 8e) . We further found that exogenous expression of wild-type (WT) STAT3 increased and dominant-negative (DN) STAT3 suppressed CLN-mediated augmentation of CCh-induced p-ERK (Figure 6c) .
To examine the role of the JAK2/STAT3 axis in M 1 mAChR function in vivo, we first injected ICR mice with CCh (Figure 6d ). At 30 min after i.p. injection of CCh, hippocampal lysates from mice with or without CCh injection were analyzed by IB. As expected, p-ERK levels were substantially increased by i.p. CCh injection in a dose-dependent fashion (Figure 6d ). Pretreatment with CLN by i.n. administration dosedependently augmented the CCh-evoked ERK phosphorylation in vivo, as observed in vitro (Figure 6e) . To examine the effect of DN-STAT3 on CCh-induced p-ERK in vivo, we injected adenoviruses encoding LacZ or DN-STAT3 into both sides of the hippocampus 39 ( Figure 6f; Supplementary Figure 9 ). Exogenous expression of DN-STAT3 in the hippocampus almost completely suppressed the increase in p-ERK by CCh injection, suggesting that M 1 mAChR-mediated 
Downregulation of the M 1 mAChR in AD models
We further examined the AD-associated alteration of the M 1 mAChR expression. We performed IF staining of the brain sections of several AD models using an anti-M 1 mAChR antibody. M 1 mAChR expression was not altered in Tg2576s at the age of 3 months although it was substantially reduced in the neurites of the hippocampi and the cortices of Tg2576s at 18 months, as compared with those of WTs (Figure 7a ). We confirmed essentially the same results in V642I-KIs at 28 months (Figure 7b ) and L286V-PS1 Tgs at 21 months (Figure 7c) . We also performed IF staining using a distinct antibody recognizing M 1 mAChR, confirming that M 1 mAChR expression was similarly reduced in V642I-KIs (Supplementary Figure 10) . IB analysis confirmed that M 1 receptor expression decreased in the hippocampi of Tg2576s at 18 months or V642I-KIs at 28 months (Figures 7d and e) . All the data suggested that the decrease in M 1 mAChR expression, which is consistent with the STAT3 inactivation, is involved in the clinical manifestation and development of AD.
Discussion
We here demonstrated that i.n. administration of CLN activates the JAK2/STAT3 axis to recover the memory function in AD models. Consistent with this finding, chronic stimulation of the hippocampal neurons by toxic Ab significantly deteriorated p-STAT3 levels, whereas removal or neutralization of Ab inversely increased p-STAT3. We also showed critical interaction between the JAK2/STAT3 axis and the cholinergic neurotransmission system. Thus, we have provided the first evidence suggesting that the JAK2/STAT3 axis may be important in the pathogenesis of AD-related memory impairment (Figure 8) .
We focused on CLN in this study because it has a potent pharmacological effect on AD models, which seems to be shared with other HN derivatives such as S14G-HN 36, 40 (unpublished data by T.C.). The targets of HN derivatives including CLN remain elusive except that there are at least two HN receptors. One is an unidentified cell-surface receptor linked to Tyr kinase activity, and the other is Bax protein located in the cytosol. Considering that the JAK2/STAT3 axis was necessary for the pharmacological effect of CLN observed in this study and that we had no evidence of transmembrane transport of CLN in vitro (unpublished data by T.C.), the memory-improving effect of CLN on AD models is likely to be mediated upon binding to the former cell-surface receptor. We also assume that STAT3-activating factors such as IL-6 STAT3 in Alzheimer's disease T Chiba et al may exert a pharmacological effect similar to CLN although this would depend not only on receptor expression levels but also on collateral pathways activated. During characterization of the pharmacological effect of CLN, we found that p-STAT3 levels in the hippocampi of Tg2576 with memory impairment were substantially reduced. IF analysis of brain sections from sporadic AD patients further revealed hippocampus-dominant reduction of p-STAT3 levels in the neuronal nuclei, suggesting that STAT3 inactivation may be closely linked to the pathogenesis of AD. Given that overproduction of soluble toxic Ab species is a widely acknowledged feature among mutants of the known FAD genes, [27] [28] [29] Ab may be the major factor accelerating STAT3 inactivation. In accordance, p-STAT3 levels in primary neurons were modulated by Ab (Figure 4 ). To the best of our knowledge, none of the known targets of Ab, such as the receptor for advanced glycation end products, 41 formyl peptide receptor (FPR)-like-1, 42 or p75 neurotrophin receptor, 43 has so far been reported to modulate the p-STAT3 levels in neurons. There are also multiple reports on intracellular signaling pathways related to AD: (1) caspase-3-mediated cleavage of APP, 44, 45 (2) taumediated Ab-neurotoxicity 46 and (3) Ab-mediated disturbance of insulin receptor signaling pathway. 47, 48 There may be some novel crosstalk between the JAK2/STAT3 axis and these pathways although there are no reports of a direct interaction of these pathways, besides the STAT3-activating effect of insulin receptor. 49 Detailed mechanisms underlying the regulation of STAT3 activity by Ab remain to be addressed in a future investigation.
In addition to the AD-related inactivation of STAT3, aging-related inactivation was also observed. This finding may be in accordance with the universally accepted notion that the most common risk factor for AD is aging. 2 We have formulated some hypotheses as to how aging causes neuronal STAT3 inactivation. First, age-dependent accumulation of neurotoxic insults, such as oxidative stress 50 and insufficiency in the protein degradation systems, 51 may inactivate STAT3. Second, the threshold at which neuronal STAT3 inactivation occurs may decrease with aging. As to this possibility, we found that p-STAT3 levels in the PHNs, which are vulnerable to AD-related toxicity, were much more easily downregulated than those in the PCNs (Figure 4) . Third, age-dependent reduction of endogenous trophic factors, which sustain neuronal STAT3 phosphorylation levels, may occur. In support of this idea, it is reported that endogenous levels of insulin-like growth factor 1 (IGF-I), which activates STAT3, decrease with aging 52 and also that IGF-1 receptor (IGF-1R), insulin receptor and insulin receptor substrate-1/2 (IRS-1/2) were disturbed in neurons of AD brains. 53 To examine how memory is regulated by the JAK2/ STAT3 axis, we first focused on STAT3-mediated transcriptional regulation of genes related to memory. Our in vitro experiments revealed that CLN induced ChAT and VAChT expression, essential genes for ADrelevant cholinergic neurons, 54 in a STAT3 activitydependent fashion. Considering that leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF), both of which can activate STAT3, are reported to have some roles in the expression of ChAT and VAChT, 55, 56 STAT3 activation is one of the key transcriptional factors for cholinergic neurons. Combined with our finding that p-STAT3 was deteriorated by toxic Ab, we have hypothesized that a substantial portion of endogenous ChAT expression in the medial septa may be dependent on the JAK2/STAT3 axis. As expected, we observed a mild reduction in the number of ChATpositive neurons in the medial septa of AG490-injected mice (Figures 5c and e) .
We also focused on the rapid CLN-mediated memory-improving effect, which seems to be distinct from the transcriptional upregulation of the cholinergic genes. To search for such rapid mechanisms, we examined the function of M 1 mAChR for several reasons: (1) a specific M 1 mAChR agonist improved hippocampal plasticity by potentiating N-methyl-D-aspartate receptor activity, 57 (2) M 1 mAChR-deficient mice showed severe memory impairment 37 and (3) M 1 mAChR agonists attenuated memory impairment in an AD model. 58 Utilizing STAT3-activating factors such as CLN and IL-6, and also ectopic expression of DN-STAT3, we found that activation of the JAK2/STAT3 axis is likely to sensitize the M 1 mAChR to CCh stimulation, probably independently of transcriptional regulation; that is, upregulation of the JAK2/STAT3 axis induces cell-surface membrane localization of M 1 mAChR whereas its downregulation induces endocytosis of M 1 mAChR. In support of this idea, endocytosis of M 1 mAChR is reported to be dependent on caveolin 2, 59 and caveolin 2 is reported to be downregulated by activation of STAT3. 60 Collectively, activation of the JAK2/STAT3 axis may reduce caveolin 2 to increase M 1 mAChR levels on the surface membrane. In accordance, we observed an age-dependent and hippocampus-dominant reduction of M 1 mAChR expression in the neuritis of several AD models in vivo (Figure 7 ).
In conclusion, we propose a novel theory accounting for memory dysfunction in AD: Ab-dependent inactivation of the JAK2/STAT3 axis in the hippocampal neurons causes memory impairment related to AD. Our findings provide not only a novel pathological hallmark in AD but also a novel target in AD therapy. Notably, the functional deterioration in the JAK2/STAT3 axis was reversed, concomitantly with memory improvement, by both CLN-mediated direct activation of the JAK2/STAT3 axis and immunological depletion of Ab.
